Cemiplimab Plus Gemcitabine for Metastatic Pancreatic Cancer
This study is looking at a new way to treat metastatic pancreatic cancer (pancreatic ductal adenocarcinoma) that has already been treated with other chemotherapy. It combines cemiplimab, an immunotherapy drug that works as a checkpoint inhibitor, with gemcitabine, a standard chemotherapy. Researchers want to see if this combination helps patients live longer. To join, you must be at least 18 years old and have pancreatic cancer that has spread, with specific changes in your tumor called ARID1A. You would have already received FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy. The study plans to enroll 43 people, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 43 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main goal is to measure how long participants live, with an initial measurement at 7 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
At a glance
Conditions
NCT06790602
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Diego
La Jolla, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Gregory P Botta, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall survival7 months
To evaluate the overall survival of participants with metastatic pancreatic adenocarcinoma harboring SWI/SNF alterations treated with cemiplimab in combination with gemcitabine as a second-line treatment.